Oakwood Capital Management LLC CA lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 4.1% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 62,925 shares of the company’s stock after selling 2,720 shares during the period. Oakwood Capital Management LLC CA’s holdings in AbbVie were worth $4,563,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also bought and sold shares of the stock. State Street Corp raised its holdings in AbbVie by 2.4% in the 1st quarter. State Street Corp now owns 72,969,530 shares of the company’s stock valued at $4,754,696,000 after acquiring an additional 1,696,042 shares in the last quarter. Wedge Capital Management L L P NC acquired a new position in AbbVie in the 1st quarter valued at approximately $46,744,000. Bank of Nova Scotia raised its holdings in AbbVie by 297.9% in the 1st quarter. Bank of Nova Scotia now owns 606,321 shares of the company’s stock valued at $39,507,000 after acquiring an additional 453,955 shares in the last quarter. Skandinaviska Enskilda Banken AB publ raised its holdings in AbbVie by 42.3% in the 1st quarter. Skandinaviska Enskilda Banken AB publ now owns 1,202,483 shares of the company’s stock valued at $78,354,000 after acquiring an additional 357,353 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in AbbVie by 58.6% in the 1st quarter. AQR Capital Management LLC now owns 940,824 shares of the company’s stock valued at $61,304,000 after acquiring an additional 347,710 shares in the last quarter. 68.25% of the stock is owned by institutional investors and hedge funds.
Shares of AbbVie Inc. (NYSE:ABBV) opened at 91.04 on Tuesday. The company’s 50-day moving average price is $85.49 and its 200-day moving average price is $72.96. AbbVie Inc. has a 52-week low of $55.06 and a 52-week high of $92.61. The company has a market capitalization of $145.13 billion, a price-to-earnings ratio of 22.39 and a beta of 1.51.
AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 28th. The company reported $1.42 EPS for the quarter, beating the consensus estimate of $1.40 by $0.02. AbbVie had a net margin of 24.77% and a return on equity of 150.27%. The business had revenue of $6.94 billion during the quarter, compared to the consensus estimate of $6.93 billion. During the same period in the previous year, the business earned $1.26 earnings per share. The company’s revenue was up 7.6% on a year-over-year basis. Equities research analysts forecast that AbbVie Inc. will post $5.53 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be given a dividend of $0.64 per share. The ex-dividend date is Thursday, October 12th. This represents a $2.56 annualized dividend and a yield of 2.81%. AbbVie’s dividend payout ratio is currently 62.90%.
COPYRIGHT VIOLATION WARNING: “AbbVie Inc. (NYSE:ABBV) Shares Sold by Oakwood Capital Management LLC CA” was published by BBNS and is the property of of BBNS. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/abbvie-inc-abbv-shares-sold-by-oakwood-capital-management-llc-ca/1697902.html.
Several equities analysts have commented on the company. Deutsche Bank AG reaffirmed a “hold” rating and issued a $66.00 price target (up previously from $65.00) on shares of AbbVie in a report on Monday, July 17th. Vetr raised AbbVie from a “hold” rating to a “buy” rating and set a $76.28 price target for the company in a report on Wednesday, July 26th. BidaskClub cut AbbVie from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $94.00 price target (up previously from $92.00) on shares of AbbVie in a report on Monday, July 17th. Finally, Zacks Investment Research raised AbbVie from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Eight research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $92.25.
In other AbbVie news, insider Henry O. Gosebruch sold 18,000 shares of the business’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $70.09, for a total transaction of $1,261,620.00. Following the sale, the insider now owns 96,074 shares of the company’s stock, valued at $6,733,826.66. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Richard A. Gonzalez sold 65,861 shares of the business’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $71.00, for a total transaction of $4,676,131.00. Following the sale, the chief executive officer now directly owns 342,353 shares in the company, valued at approximately $24,307,063. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 379,890 shares of company stock valued at $27,187,817. Company insiders own 0.23% of the company’s stock.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with our FREE daily email newsletter.